- Home
- SPKL vs CRBP Comparison
SPKL vs CRBP Comparison
Compare SPKL & CRBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPKL
- CRBP
- Stock Information
- Founded
- SPKL 2021
- CRBP 2009
- Country
- SPKL United States
- CRBP United States
- Employees
- SPKL N/A
- CRBP N/A
- Industry
- SPKL
- CRBP Biotechnology: Pharmaceutical Preparations
- Sector
- SPKL
- CRBP Health Care
- Exchange
- SPKL Nasdaq
- CRBP Nasdaq
- Market Cap
- SPKL 174.6M
- CRBP 143.7M
- IPO Year
- SPKL 2023
- CRBP N/A
- Fundamental
- Price
- SPKL $10.67
- CRBP $11.93
- Analyst Decision
- SPKL
- CRBP Strong Buy
- Analyst Count
- SPKL 0
- CRBP 8
- Target Price
- SPKL N/A
- CRBP $62.00
- AVG Volume (30 Days)
- SPKL 31.3K
- CRBP 256.8K
- Earning Date
- SPKL 01-01-0001
- CRBP 03-11-2025
- Dividend Yield
- SPKL N/A
- CRBP N/A
- EPS Growth
- SPKL N/A
- CRBP N/A
- EPS
- SPKL 0.19
- CRBP N/A
- Revenue
- SPKL N/A
- CRBP N/A
- Revenue This Year
- SPKL N/A
- CRBP N/A
- Revenue Next Year
- SPKL N/A
- CRBP N/A
- P/E Ratio
- SPKL $57.56
- CRBP N/A
- Revenue Growth
- SPKL N/A
- CRBP N/A
- 52 Week Low
- SPKL $10.18
- CRBP $7.30
- 52 Week High
- SPKL $11.95
- CRBP $61.90
- Technical
- Relative Strength Index (RSI)
- SPKL 61.48
- CRBP 39.08
- Support Level
- SPKL $10.63
- CRBP $11.02
- Resistance Level
- SPKL $10.68
- CRBP $13.28
- Average True Range (ATR)
- SPKL 0.02
- CRBP 0.74
- MACD
- SPKL 0.00
- CRBP 0.16
- Stochastic Oscillator
- SPKL 85.71
- CRBP 40.27
About SPKL Spark I Acquisition Corp.
Spark I Acquisition Corp is a Blank check company.
About CRBP Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.